Skip to main content

Table 3 Mutually adjusted factors associated with shift to NOACS

From: Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends

 

OR (95% CI)

p-value

Age per 1 year increment

0.992 (0.987; 0.997)

0.003

Female sex

1.18 (1.07; 1.29)

0.001

Smoking

  

 Never

1.0 (ref.)

 

 Ever

0.71 (0.61; 0.84)

< 0.001

 Unknown

0.47 (0.31; 0.72)

< 0.001

District of inhabitance

  

 North

1.0 (ref.)

 

 Sharon

1.10 (0.94; 1.28)

0.240

 South

1.30 (1.13; 1.51)

< 0.001

 Center

1.01 (0.87; 1.17)

0.934

 Jerusalem/ Hashfela

1.11 (0.97; 1.28)

0.138

Baseline comorbidity

  

CHADS2 score

0

1.0 (ref.)

 

1

2.15 (1.72; 2.69)

< 0.001

≥ 2

2.81 (2.23; 3.53)

< 0.001

Hyperlipidemia

1.45 (1.26; 1.66)

< 0.001

Concomitant medications

  

ARBs

1.26 (1.14; 1.39)

< 0.001

Antithrombotics

1.15 (1.03; 1.29)

0.014

Ca channel blockers

0.92 (0.83; 1.01)

0.090

Diuretics

0.84 (0.72; 0.98)

0.024

Nitrates

0.63 (0.39; 1.02)

0.062

Incident 2012–2015

1.73 (1.52; 1.98)

< 0.001

  1. NOAC new oral anticoagulants, SES socioeconomic status, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, SD standard deviation, CHADS congestive heart failure, hypertension, age>75, diabetes mellitus, stroke/transient ischemic event; scale of 0 (lowest risk) to 6 (highest risk). CHA2DS2-VASc Congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic event, sex, vascular disease history; scale of 0 (lowest risk) to 9 (highest risk)
  2. Bold means statistically significant, i.e. p < 0.05
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us